Pharmaceutical composition for preventing or treating diabetes containing TENC1 expression or activity suppressor
US9402856B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 14, 2013 |
| Grant date | Aug 2, 2016 |
| Priority date | — |
| Expiry date | Jan 14, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/042
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which includes a TENC1 (tensin like C1 domain-containing phosphatase) expression or activity suppressor, and, more specifically, relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which either suppresses the degradation of IRS-1 (insulin receptor substrate-1) or suppresses the phosphorylation of IRS-1 due to the PTPase activity of TENC1. The pharmaceutical composition according to the present invention, which is for preventing or treating diabetes or a complication of diabetes and comprises the TENC1 expression or activity suppressor as an active ingredient, can be expected to be widely usable in preventing and treating diabetes or a complication of diabetes since the pharmaceutical composition can effectively prevent the muscular dystrophy and reduction in sugar adsorption that occur due to reduction in IRS-1 by suppressing degradation of IRS-1 caused by TENC1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.